Pharmafile Logo
Pharmafocus logo
Advanced Search

Alzheimer’s

Showing 15 posts of 151 posts found.

brain-770044_960_720

Lilly’s drug for early Alzheimer’s shows promising results

August 6, 2025
Medical Communications, Research and Development Alzheimer's, Eli Lilly, Neurology, dementia

Eli Lilly (Lilly) has announced positive new data from the long-term extension of its phase 3 study, showing that Kisunla …

News

Eli Lilly’s Kisunla approved by FDA for Alzheimer’s treatment

July 3, 2024
Medical Communications Alzheimer's, Eli Lilly, Kisunla, Neurology

Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Kisunla (donanemab-azbt, 350mg/20ml once-monthly injection for …

News
robina-weermeijer-ihfopazzjhm-unsplash_5

FDA accepts Eisai’s Leqembi sBLA for early AD treatment

June 11, 2024
Medical Communications Alzheimer's, Biogen, FDA, Neurology, sBLA

Eisai and Biogen have announced that the US Food and Drug Administration (FDA) has accepted Eisai’s supplemental biologics license application …

News

Voyager Therapeutics shares data from preclinical programmes for Alzheimer’s treatment

February 21, 2024
Research and Development Alzheimer's, Neurology, Voyager Therapeutics, preclinical

Voyager Therapeutics has announced new data from is two preclinical programmes targeting pathological tau for the treatment of Alzheimer’s disease …

News
robina-weermeijer-so1l3jsdd3y-unsplash_2

Eisai shares new data for Leqembi for Alzheimer’s treatment

October 26, 2023
Research and Development Alzheimer's, Biogen, Eisai, Neurology, lecanemab

Eisai and Biogen have announced that Eisai has shared new data for Leqembi (lecanemab-irmb) 100mg/mL injection for intravenous (IV) use …

News
brain_anatomy_medical_head_skull_digital_3_d_x_ray_xray_psychedelic_3720x2631

Axol Bioscience and StrataStem collaborate to deliver ‘clinical trial in a dish’ for Alzheimer’s disease

June 7, 2023
Research and Development Alzheimer's, Axol Bioscience, Neurology, StrataStem

Pluripotent stem cell technology provider Axol Bioscience has signed an exclusive agreement with UK-based StrataStem to access and commercialise its …

News

Eli Lilly to seek FDA approval for experimental Alzheimer’s drug

June 25, 2021
Medical Communications Alzheimer's, Eli Lilly, FDA

Eli Lilly plans to seek accelerated FDA approval for its experimental Alzheimer’s drug donanemab, announcing plans on Thursday to file …

News
evonik__chemie_foto_001

Evonik and Cassava Sciences enter supply agreement for Alzheimer’s drug candidate

March 10, 2021
Research and Development Alzheimer's, Cassava Sciences, Evonik

Evonik has entered into an agreement to supply Cassava Sciences with large-scale, clinical-grade quantities of simufilam, a drug candidate for …

News
lilly_building_with_american_flag_web

Eli Lilly’s Alzheimer’s drug slows clinical decline in Phase II trial

January 11, 2021
Sales and Marketing Alzheimer's, Eli Lilly

Eli Lilly’s donanemab has shown significant slowing of decline in a composite measure of cognition and daily function in patients …

News
trialy

Leukaemia drug nilotinib shows promise against Alzheimer’s in small clinical study

May 29, 2020
Medical Communications Alzheimer's, leukaemia

The leukemia drug nilotinib has shown promise in reducing the effects of Alzheimer’s disease and while having safe and minimal …

News
alzheimers

Roche’s experimental Alzheimer’s drug does not meet primary endpoint in clinical trials

February 10, 2020
Sales and Marketing Alzheimer's, Roche, roche Alzheimer

Roche has said its experimental drug, gantenerumab, did not meet its primary endpoint in people who have an inherited form …

News
biogen_austria_238

Biogen picks up Pfizer’s Phase 1 therapy for Alzheimer’s symptoms in potential $700m deal

January 14, 2020
Manufacturing and Production, Sales and Marketing Alzheimer's, Biogen, Pfizer, pharma

Biogen has entered into an agreement with Pfizer to acquire the latter’s Phase 1 candidate PF-05251749 in order to develop …

News
lda1_last_capsule_sm

LSD treatment for Alzheimer’s patients proves safe in recent trial

December 19, 2019
Business Services Alzheimer's, FDA, LSD, Magic mushrooms, psilocybin

The results of a Phase 1 clinical trial shows that Lysergic Acid Diethylamide (LSD) can be microdosed safely, and potentially …

News
shutterstock_38078521

China green lights first novel Alzheimer’s therapy since 2003

November 4, 2019
Sales and Marketing Alzheimer's, China, Green Valley, Oligomannate, pharma

Shanghai Green Valley Pharmaceuticals has announced that its therapy Oligomannate (GV-971) has secured marketing approval from China’s National Medical Products Administration (NMPA) …

News

Axon seeks global partner after positive Phase 2 data for Alzheimer’s vaccine

September 10, 2019
Manufacturing and Production, Sales and Marketing Alzheimer's, Alzheimers, Axon

Axon Neuroscience has announced data from its Phase 2 trial ADAMANT for the first-in-class vaccine AADvac1 to slow the progression …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025